I still haven't seen a reason why an FDA approved drug with 30 million in annual sales and an additional pipeline wouldn't be worth 20 million from a diversification angle seeing as they have funds for this next AD trial. If anyone can find a drug that sold cheaper i would like to take a look. Might not be something I would have done but they told us last October this was a direction they were going.
Market Data 
Markets 
AI
